ZVRA Quote, Financials, Valuation and Earnings

NovaBay Pharmaceuticals, Inc. has a net margin of -2.09% compared to Zevra Therapeutics, Inc.'s net margin of -255.85%. Zevra Therapeutics, Inc.'s return on equity of 44.06% beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.

Zevra Therapeutics, Inc. has a consensus price target of $23.10, signalling upside risk potential of 160.31%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -22.02%. Given that Zevra Therapeutics, Inc. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe Zevra Therapeutics, Inc. is more attractive than NovaBay Pharmaceuticals, Inc..

Zevra Therapeutics, Inc. has a beta of 1.009, which suggesting that the stock is 0.92699999999999% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.569, suggesting its less volatile than the S&P 500 by 43.103%.

Zevra Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. Zevra Therapeutics, Inc. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Zevra Therapeutics, Inc. quarterly revenues are $26.1M, which are larger than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. Zevra Therapeutics, Inc.'s net income of -$544K is higher than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, Zevra Therapeutics, Inc.'s price-to-earnings ratio is 13.73x while NovaBay Pharmaceuticals, Inc.'s PE ratio is 1.83x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zevra Therapeutics, Inc. is 5.61x versus 2.12x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Nektar Therapeutics has a net margin of -2.09% compared to Zevra Therapeutics, Inc.'s net margin of -301.29%. Zevra Therapeutics, Inc.'s return on equity of 44.06% beat Nektar Therapeutics's return on equity of -327.67%.

Zevra Therapeutics, Inc. has a consensus price target of $23.10, signalling upside risk potential of 160.31%. On the other hand Nektar Therapeutics has an analysts' consensus of $107.29 which suggests that it could grow by 85.97%. Given that Zevra Therapeutics, Inc. has higher upside potential than Nektar Therapeutics, analysts believe Zevra Therapeutics, Inc. is more attractive than Nektar Therapeutics.

Zevra Therapeutics, Inc. has a beta of 1.009, which suggesting that the stock is 0.92699999999999% more volatile than S&P 500. In comparison Nektar Therapeutics has a beta of 1.268, suggesting its more volatile than the S&P 500 by 26.844%.

Zevra Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nektar Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Zevra Therapeutics, Inc. pays -- of its earnings as a dividend. Nektar Therapeutics pays out -- of its earnings as a dividend.

Zevra Therapeutics, Inc. quarterly revenues are $26.1M, which are larger than Nektar Therapeutics quarterly revenues of $11.8M. Zevra Therapeutics, Inc.'s net income of -$544K is higher than Nektar Therapeutics's net income of -$35.5M. Notably, Zevra Therapeutics, Inc.'s price-to-earnings ratio is 13.73x while Nektar Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zevra Therapeutics, Inc. is 5.61x versus 59.49x for Nektar Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of -2.09% compared to Zevra Therapeutics, Inc.'s net margin of --. Zevra Therapeutics, Inc.'s return on equity of 44.06% beat Palatin Technologies's return on equity of --.

Zevra Therapeutics, Inc. has a consensus price target of $23.10, signalling upside risk potential of 160.31%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 7338.9%. Given that Palatin Technologies has higher upside potential than Zevra Therapeutics, Inc., analysts believe Palatin Technologies is more attractive than Zevra Therapeutics, Inc..

Zevra Therapeutics, Inc. has a beta of 1.009, which suggesting that the stock is 0.92699999999999% more volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.939, suggesting its less volatile than the S&P 500 by 6.103%.

Zevra Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Zevra Therapeutics, Inc. pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

Zevra Therapeutics, Inc. quarterly revenues are $26.1M, which are larger than Palatin Technologies quarterly revenues of --. Zevra Therapeutics, Inc.'s net income of -$544K is higher than Palatin Technologies's net income of --. Notably, Zevra Therapeutics, Inc.'s price-to-earnings ratio is 13.73x while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zevra Therapeutics, Inc. is 5.61x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.

XOMA Royalty Corp. has a net margin of -2.09% compared to Zevra Therapeutics, Inc.'s net margin of 52.48%. Zevra Therapeutics, Inc.'s return on equity of 44.06% beat XOMA Royalty Corp.'s return on equity of 17.31%.

Zevra Therapeutics, Inc. has a consensus price target of $23.10, signalling upside risk potential of 160.31%. On the other hand XOMA Royalty Corp. has an analysts' consensus of $70.67 which suggests that it could grow by 127.01%. Given that Zevra Therapeutics, Inc. has higher upside potential than XOMA Royalty Corp., analysts believe Zevra Therapeutics, Inc. is more attractive than XOMA Royalty Corp..

Zevra Therapeutics, Inc. has a beta of 1.009, which suggesting that the stock is 0.92699999999999% more volatile than S&P 500. In comparison XOMA Royalty Corp. has a beta of 0.941, suggesting its less volatile than the S&P 500 by 5.919%.

Zevra Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. XOMA Royalty Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.54 per share. Zevra Therapeutics, Inc. pays -- of its earnings as a dividend. XOMA Royalty Corp. pays out 39.59% of its earnings as a dividend. XOMA Royalty Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Zevra Therapeutics, Inc. quarterly revenues are $26.1M, which are larger than XOMA Royalty Corp. quarterly revenues of $9.4M. Zevra Therapeutics, Inc.'s net income of -$544K is lower than XOMA Royalty Corp.'s net income of $10.3M. Notably, Zevra Therapeutics, Inc.'s price-to-earnings ratio is 13.73x while XOMA Royalty Corp.'s PE ratio is 41.76x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zevra Therapeutics, Inc. is 5.61x versus 10.83x for XOMA Royalty Corp.. Usually stocks with elevated PS ratios are considered overvalued.